<DOC>
	<DOC>NCT01865786</DOC>
	<brief_summary>This is a prospective, observational study to describe pregnancy outcomes among HIV-1 uninfected pregnant women who are taking emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (TruvadaÂ®) for a pre-exposure prophylaxis (PrEP) indication nested in the Antiretroviral Pregnancy Registry (APR). Information on subjects is provided to the APR prospectively (prior to the outcome of the pregnancy being known) through their healthcare provider, with follow-up obtained from the healthcare provider following determination of the pregnancy outcome.</brief_summary>
	<brief_title>A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key Pregnant women Part of the prospective arm of the APR Target Group Inclusion Criteria HIV1 Negative Choosing to remain on FTC/TDF for PrEP during pregnancy or, Choosing to discontinue FTC/TDF for PrEP during pregnancy Comparison Group Inclusion Criteria HIV1 Positive On antiretroviral therapy Key This is an observational nested study and will monitor all reported exposures without intervention/exclusion. Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FTC/TDF</keyword>
	<keyword>Truvada</keyword>
	<keyword>PrEP</keyword>
	<keyword>Antiretroviral Pregnancy Registry</keyword>
</DOC>